Our Pricing

Understanding the Wegovy BMI Requirement UK: Eligibility Criteria for Prescription Weight Loss

The Wegovy BMI requirement UK is a crucial factor in determining eligibility for this prescription weight loss treatment. At Cured Pharmacy, we help patients understand whether they meet the clinical criteria for semaglutide therapy, which typically requires a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity[1]. Our UK-registered clinical team assesses each patient individually to ensure safe, appropriate prescribing in line with MHRA and NICE guidance.

What Is the Wegovy BMI Requirement UK for Prescription Eligibility?

The Wegovy BMI requirement UK follows established clinical guidelines that prioritise patient safety and treatment appropriateness. In the UK, Wegovy (semaglutide 2.4mg) is licensed for adults with a body mass index of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea[1]. These thresholds align with NICE recommendations and reflect the inclusion criteria used in the pivotal STEP clinical trial programme[2].

At Cured Pharmacy, our prescribers assess each patient's BMI alongside their medical history, current medications, and weight loss goals during a free online consultation. This individualised approach ensures that Wegovy is prescribed only when clinically appropriate and when lifestyle interventions alone have not achieved sufficient weight loss. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all clinical protocols to maintain the highest standards of patient care and regulatory compliance.

How BMI Thresholds for Wegovy Prescription Are Calculated in the UK

Understanding your BMI is the first step in determining whether you meet the Wegovy BMI requirement UK criteria. Body mass index is calculated by dividing your weight in kilograms by the square of your height in metres (kg/m²). For example, a person weighing 90kg and standing 1.75m tall would have a BMI of approximately 29.4 kg/m². This simple calculation provides a standardised measure that UK prescribers use to assess obesity and weight-related health risks[3].

However, BMI is not the sole determinant of eligibility. UK prescribers also consider waist circumference, ethnicity-specific risk factors, and the presence of comorbid conditions. For individuals of South Asian, Chinese, or Black African descent, lower BMI thresholds may apply due to increased metabolic risk at lower body weights[1]. At Cured Pharmacy, our clinical assessment captures these nuances to ensure equitable access to Wegovy for all eligible patients, regardless of ethnic background.

Comorbidities That Lower the Wegovy BMI Requirement UK Threshold

Patients with a BMI of 27 kg/m² or above may qualify for Wegovy if they have at least one weight-related comorbidity. These include type 2 diabetes, prediabetes, hypertension, dyslipidaemia, cardiovascular disease, non-alcoholic fatty liver disease, polycystic ovary syndrome, or obstructive sleep apnoea[2]. The presence of these conditions significantly increases the health risks associated with excess weight, making pharmacological intervention clinically justified even at a lower BMI threshold.

During your online consultation at Cured Pharmacy, you will be asked to disclose any diagnosed comorbidities and current medications. This information allows our prescribers to assess whether you meet the expanded Wegovy BMI requirement UK criteria and whether semaglutide therapy is safe and appropriate for your individual circumstances. All consultations are conducted by UK-registered clinicians and typically take under three minutes to complete.

Clinical Evidence Supporting the Wegovy BMI Requirement UK Guidelines

The Wegovy BMI requirement UK is grounded in robust clinical trial data from the STEP programme, which enrolled over 4,500 adults with obesity or overweight with comorbidities. In the landmark STEP 1 trial, participants with a mean baseline BMI of 37.9 kg/m² achieved an average weight loss of 14.9% over 68 weeks when treated with semaglutide 2.4mg, compared to 2.4% with placebo[2]. These results demonstrated that Wegovy is highly effective in the target population defined by current BMI thresholds.

Importantly, subgroup analyses showed consistent efficacy across different baseline BMI categories, including those with BMI 27-30 kg/m² who had weight-related comorbidities. This evidence supports the dual-threshold approach used in UK prescribing guidelines and reinforces the importance of individualised assessment. At Cured Pharmacy, we provide Wegovy at £69.00 ensuring that eligible patients can access this evidence-based treatment at competitive UK pricing, subject to prescriber approval.

What to Expect During Your Wegovy BMI Requirement UK Assessment at Cured Pharmacy

Your journey begins with a free online clinical assessment that evaluates whether you meet the Wegovy BMI requirement UK criteria. You will be asked to provide your current height and weight, medical history, current medications, and details of any weight-related health conditions. Our UK-registered prescribers review this information to calculate your BMI and determine whether Wegovy is a safe and appropriate option for you[3].

If approved, your prescription is issued electronically and dispensed by our GPhC-registered pharmacy (9012511). Wegovy is available from £69.00 and we offer discreet next-day delivery across the UK. All medicines are genuine, UK-licensed products sourced from reputable wholesalers. Our transparent pricing means you see the full cost upfront, with no hidden fees or subscription traps. New customers can Save £20 off their first order using code Weightlossnew.

Common Reasons for Not Meeting the Wegovy BMI Requirement UK Criteria

Some patients may not meet the Wegovy BMI requirement UK thresholds due to a BMI below 27 kg/m², absence of weight-related comorbidities, or contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2[1]. Pregnant or breastfeeding women are also ineligible, as are individuals with severe gastrointestinal disease or a history of pancreatitis.

If you do not qualify for Wegovy, our prescribers may recommend alternative weight loss treatments such as Orlistat, Mysimba, or Saxenda, depending on your clinical profile. Cured Pharmacy offers a comprehensive range of MHRA-licensed weight loss medications, all subject to the same rigorous clinical assessment process to ensure patient safety and treatment efficacy.

How the Wegovy BMI Requirement UK Compares to Other Weight Loss Medications

While the Wegovy BMI requirement UK is set at 30 kg/m² or 27 kg/m² with comorbidities, other weight loss medications have different eligibility criteria. Orlistat, for example, is licensed for individuals with a BMI of 28 kg/m² or above, making it accessible to a slightly broader population[3]. Saxenda (liraglutide 3mg) shares the same BMI thresholds as Wegovy, while Mounjaro (tirzepatide) follows similar criteria but is primarily licensed for type 2 diabetes, with weight loss as a secondary benefit.

Understanding these differences helps patients and prescribers select the most appropriate treatment. At Cured Pharmacy, we stock all major weight loss medications and provide clear, evidence-based guidance during your consultation. Our clinical team considers your BMI, comorbidities, previous treatment responses, and personal preferences to recommend the option most likely to achieve safe, sustainable weight loss.

Maintaining Eligibility: Ongoing Monitoring After Meeting the Wegovy BMI Requirement UK

Meeting the Wegovy BMI requirement UK is only the first step in a longer-term weight management programme. NICE guidance recommends that patients are reviewed after 12 weeks of treatment to assess response, defined as at least 5% weight loss from baseline[1]. If this threshold is not met, continuation of Wegovy may not be appropriate, and alternative strategies should be considered.

At Cured Pharmacy, we support ongoing treatment through repeat prescription services and access to our clinical team for any questions or concerns. We encourage patients to combine Wegovy with lifestyle modifications, including a reduced-calorie diet and increased physical activity, as recommended in all major clinical trials[2]. Our pharmacists are available by phone (+44 116 4646009) to provide guidance on injection technique, managing side effects, and optimising treatment outcomes. All follow-up prescriptions are subject to continued clinical suitability and prescriber approval.

What Happens If Your BMI Falls Below the Wegovy Requirement UK Threshold During Treatment?

As you lose weight on Wegovy, your BMI will naturally decrease. If your BMI falls below the original Wegovy BMI requirement UK threshold of 30 kg/m² (or 27 kg/m² with comorbidities), your prescriber will assess whether continued treatment is appropriate. In many cases, Wegovy may be continued for weight maintenance, particularly if discontinuation has previously led to weight regain or if significant comorbidities persist[2].

Clinical judgement is paramount in these decisions. Some patients may transition to a lower maintenance dose, while others may discontinue Wegovy and focus on lifestyle measures alone. At Cured Pharmacy, our prescribers apply a patient-centred approach that balances clinical guidelines with individual circumstances, always prioritising long-term health outcomes over rigid adherence to BMI thresholds.

Scientific References

1. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity (TA875). NICE. [accessed 15 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Public assessment report: Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg solution for injection in pre-filled pen. MHRA. [accessed 15 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.